First mRNA Cancer Vaccine Succeeds in Phase III Trial

Adding the mRNA-based individualized neoantigen vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death by 42%, according to the results of the phase III INTerpath-0001 trial. The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.

Publication Details

Journal
Cancer Discovery
Published
2026-10-26
DOI
https://doi.org/10.1158/2159-8290.cd-nw2026-0098
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

First mRNA Cancer Vaccine Succeeds in Phase III Trial

1 links
Cancer Discovery
Cancer Immunotherapy and Biomarkers
article

First mRNA Cancer Vaccine Succeeds in Phase III Trial

article en

Abstract

Adding the mRNA-based individualized neoantigen vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death by 42%, according to the results of the phase III INTerpath-0001 trial. The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.

Cancer Discovery
Openalex Percentile: Top 16%
Cancer Immunotherapy and Biomarkers
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
First mRNA Cancer Vaccine Succeeds in Phase III Trial · Cancer Discovery (2026) | TGRS Research Map | TGRS